Schistosomes: the road from host–parasite interactions to vaccines in clinical trials

Càpron, André; Riveau, Gilles; Capron, Moníque; Trottein, François

doi:10.1016/j.pt.2005.01.003

Cited by 131 publications

(111 citation statements)

References 70 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…There are two main reasons for this: the availability of an effective and cheap drug, praziquantel, has contributed to the wrong perception that chemotherapy would represent the final solution for the control of schistosomiasis, and the disability adjusted life years as a measure of the impact of disease has been under evaluated because of rebound morbidity following chemotherapeutic intervention (Capron et al, 2005). Prevalence is thought to be rising mainly due to increasing travelers from the USA and Europe to these endemic regions for business or leisure.…”

Section: Introductionmentioning

confidence: 99%

Schistosoma haematobium: Identification of new estrogenic molecules with estradiol antagonistic activity and ability to inactivate estrogen receptor in mammalian cells

Botelho

Soares

Vale

et al. 2010

Experimental Parasitology

View full text Add to dashboard Cite

a b s t r a c tWe have previously identified the expression of an estradiol (E2)-related molecule by Schistosoma haematobium total antigen (Sh). We now show that this molecule has an antagonistic effect of estradiol in vitro. Our results are consistent with the existence of an estrogenic molecule that antagonizes the activity of estradiol. We found evidence for this molecule as we identified and characterized by mass spectrometry new estrogenic molecules previously unknown, present in schistosome worm extracts and sera of Schistosoma-infected individuals. We also show that Sh is able to interact in vitro with estrogen receptor (ER), explaining how host endocrine system can favor the establishment of schistosomes. These findings highlight the exploitation of the host endocrine system by schistosomes and represent an additional regulatory component of schistosome development that defines a novel paradigm enabling host-parasite interactions. The identification of these molecules opens new ways for the development of alternative drugs to treat schistosomiasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Schistosoma haematobium: Identification of new estrogenic molecules with estradiol antagonistic activity and ability to inactivate estrogen receptor in mammalian cells

Botelho

Soares

Vale

et al. 2010

Experimental Parasitology

View full text Add to dashboard Cite

show abstract

“…In addition, all these antigens, with the exception of Sm23, are not expected to display an extracellular location and are instead cytosolic or cytoskeletal components, which raises doubts about the mechanisms of how they trigger the immune effector system [21]. Currently, Phase I and II clinical trials in humans are underway using S. hematobium glutathione-S-transferase; on the basis of previous results it is hoped that vaccination with this antigen should help to limit pathology and improve the efficiency of Praziquantel [22].…”

Section: Introductionmentioning

confidence: 99%

Schistosomes—proteomics studies for potential novel vaccines and drug targets

DeMarco

Verjovski-Almeida

2009

Drug Discovery Today

View full text Add to dashboard Cite

Schistosomiasis is a major health problem and, despite decades of research, only one effective drug, Praziquantel is currently available. Recent expansion of sequence databases on Schistosoma mansoni and S. japonicum has permitted a wealth of novel proteomic studies on several aspects of the organization and development of the parasite in the human host. This unprecedented accumulation of molecular data is allowing a more rational approach to propose drug targets and vaccine candidates, such as proteins located at the parasite surface. Successful preliminary trials of two vaccine candidates that have been detected at the parasite surface by proteomics give grounds for believing that such an approach may provide a fresh start for the field.

show abstract

“…In future studies it would be instructive to clarify the immuno-modulatory mechanisms responsible for its vaccine action along the lines reported by Capron and coworkers with recombinant 28 kDa glutathione-S-transferase of Schistosoma haematobium (rShGST28), which represents the first schistosome vaccine tested in humans. Capron et al (2005) noted that, in initial trials, rShGST28 produced in yeast and delivered in alum is safe and that it can engender significant antischistosomal effects. Given that S. japonicum infection is a true zoonosis, unlike the other species of schistosomes of public health consequence, it has been suggested that if a transmission blocking veterinary vaccine developed for bovines can be put into practice in combination with other control strategies such as human chemotherapy, elimination of S. japonicum from China may be achievable (McManus 2005).…”

Section: Discussionmentioning

confidence: 99%

Recombinant tegumental protein Shistosoma japonicum very lowdensity lipoprotein binding protein as a vaccine candidate against Schistosoma japonicum

Gan

Shen

Wang

et al. 2006

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

A polyhistidine-tagged recombinant tegumental protein Schistosoma japonicum very lowdensity lipoprotein binding protein (SVLBP) from adult Schistosoma japonicum was expressed in Escherichia coli. The affinity purified rSVLBP was used to vaccinate mice. The worm numbers and egg deposition recovered from the livers and veins of the immunized mice were 33.5% and 47.6% less than that from control mice, respectively (p<0.05). There was also a marked increase in the antibody response in vaccinated mice: the titer of IgG1 and IgG2a, IgG2b in the vaccinated group was significantly higher than that in the controls (>1:6,400 in total IgG). In a comparison of the reactivity of sera from healthy individuals and patients with rSVLBP, recognition patterns against this parasite tegumental antigen varied among different groups of the individuals. Notably, the average titres of anti-rSVLBP antibody in sera from faecal egg-negative individuals was significantly higher than that in sera from the faecal egg-positives, which may be reflect SVLBP-specific protection. These results suggested that the parasite tegumental protein SVLBP was a promising candidate for further investigation as a vaccine antigen for use against Asian schistosomiasis

show abstract

Schistosomes: the road from host–parasite interactions to vaccines in clinical trials

Cited by 131 publications

References 70 publications

Schistosoma haematobium: Identification of new estrogenic molecules with estradiol antagonistic activity and ability to inactivate estrogen receptor in mammalian cells

Schistosoma haematobium: Identification of new estrogenic molecules with estradiol antagonistic activity and ability to inactivate estrogen receptor in mammalian cells

Schistosomes—proteomics studies for potential novel vaccines and drug targets

Recombinant tegumental protein Shistosoma japonicum very lowdensity lipoprotein binding protein as a vaccine candidate against Schistosoma japonicum

Contact Info

Product

Resources

About